Muscular Dystrophy (MD) Zebrafish Model Development Service

Are you currently facing long drug development cycles, difficulty in preclinical validation, or challenges in identifying effective therapies for muscular dystrophy? Our Muscular dystrophy (MD) zebrafish models service helps you accelerate drug discovery, obtain robust in vivo data, and streamline therapeutic validation through advanced genetic engineering, high-throughput screening platforms, and real-time in vivo visualization.

MD is a group of debilitating genetic disorders causing progressive muscle degeneration. Effective treatments remain elusive, highlighting the urgent need for advanced research tools. Zebrafish models offer a powerful, cost-effective, and rapid alternative to traditional preclinical models, enabling deeper understanding of disease mechanisms and accelerating therapeutic development. Their genetic homology and optical transparency provide unparalleled in vivo insights, supporting the credibility of their utility in MD research.

How Our Muscular Dystrophy (MD) Zebrafish Models Can Assist Your Project?

At Creative Biolabs, we provide specific deliverables and solutions designed to significantly advance your muscular dystrophy research. You can expect early efficacy data, comprehensive toxicity profiles, validated therapeutic targets, and optimized lead compounds, all grounded in robust in vivo evidence. Our services are tailored to provide actionable insights, helping you make informed decisions quickly.

Discover How We Can Help - Request a Consultation

Workflow:

Our streamlined workflow ensures efficient and high-quality results, making it clear to potential clients what is involved at each stage:

Required Starting Materials: To initiate your project, clients typically provide:
- Target Gene/Mutation Information: Specific genetic details relevant to the MD subtype you are investigating.
- Compound Libraries: If the project involves drug screening, access to your chemical compound libraries for testing.
- Specific Research Questions/Hypotheses: Clear objectives and scientific questions you aim to answer with the zebrafish model

Fig.1 Workflow of our Muscular Dystrophy (MD) Zebrafish Models Development Services Can Assist Your Project. (Creative Biolabs Original)

Final Deliverables:
- Detailed Study Reports: Comprehensive documentation of methodologies, results, and conclusions.
- Raw and Analyzed Phenotypic Data: All quantitative data from assays, ready for your analysis.
- Identified Lead Compounds/Validated Therapeutic Targets: Specific molecules or targets showing promise in the model.
- High-Resolution Images/Videos: Visual evidence of muscle pathology and therapeutic effects.
Estimated Timeframe: The typical timeframe for this service ranges from 8 to 16 weeks, depending on the complexity of the model, the scale of the screening campaign, and the specific assay requirements. For rapid efficacy assessments, initial data can often be established in as little as 4 days.

Why Choose Us?

Choosing CBL for your MD research means partnering with a team that delivers unparalleled advantages and unique features. Our expertise ensures rapid turnaround, exceptional cost-effectiveness, and robust high-throughput capabilities, all built upon the strong human genetic homology and optical transparency of zebrafish models. Our dedicated scientific team and portfolio of validated models are committed to your success.

Experience the Advantage - Get a Quote Today

Customer Reviews:

[Accelerated Screening] Using CBL's Muscular MD zebrafish models in our research has significantly improved our high-throughput drug screening efficiency. The rapid turnaround of efficacy data, often within days, allowed us to quickly prioritize lead compounds and de-risk our pipeline. Their expertise in developing fluorescently-tagged alleles was particularly valuable for early disease detection. June 2025, Dr. An S*h.

[Cost-Effective Validation] The cost-effectiveness and scalability of CBL's MD zebrafish Models facilitated comprehensive in vivo validation of our gene therapy constructs. We obtained robust data on muscle integrity and functional recovery without the prohibitive costs associated with larger animal models, making our budget go further. May 2025, Prof. Ma K*r.

[Translational Insights] CBL's deep understanding of zebrafish muscle biology, including slow-red and fast-white fiber analysis, provided crucial insights into the mechanisms of our therapeutic candidate for LGMD. The detailed phenotypic and biomarker assessments (mRNA/microRNA) seamlessly integrated with our mammalian studies, strengthening our translational data package. April 2025, Dr. Js W*n.

Muscular Dystrophy (MD) Zebrafish Models

MD represents a group of devastating genetic disorders characterized by progressive muscle weakness and degeneration. Affecting millions worldwide, MD imposes a profound burden on patients and their families, with many forms leading to severe disability and premature death. Despite significant research efforts, effective treatments remain elusive for many MD subtypes, underscoring the urgent need for innovative research tools that can accelerate the discovery and validation of novel therapies.

At CBL, we recognize this critical need. With over two decades of experience at the forefront of biological research, we have witnessed firsthand the transformative impact of robust preclinical models. Among these, the zebrafish (Danio rerio) has emerged as an exceptionally powerful and versatile platform, revolutionizing our approach to understanding and combating MD.

Pioneering MD Modeling in Zebrafish: From Duchenne to Limb-Girdle

Over the past decade, CBL has leveraged these advantages to develop and characterize a comprehensive suite of zebrafish models for various forms of MD. Our expertise spans:

Models	Description
Duchenne Muscular Dystrophy (DMD)	Zebrafish models lacking dystrophin exhibit characteristic muscle degeneration, impaired locomotion, and compromised cardiac function, faithfully recapitulating key aspects of human DMD. These models closely resemble human DMD in symptom severity, allowing for easy monitoring of both cardiac and skeletal muscle phenotypes and biomarkers. They are invaluable for testing gene therapies, exon-skipping strategies, and small molecule interventions.
Limb-Girdle Muscular Dystrophy (LGMD)	We have established models for various LGMD subtypes by targeting genes like sarcoglycans, dysferlin, and caveolin-3 (cav3). These models enable the study of muscle repair mechanisms, the efficacy of cell-based therapies, and the role of membrane proteins in disease progression.
Congenital Muscular Dystrophy (CMD)	Zebrafish models for CMD, often involving collagen VI or laminin deficiencies (such as LAMA2-related CMD, also known as merosin deficient CMD (MDC1A)), provide crucial insights into early-onset muscle pathology and the development of supportive therapies. These models have been instrumental in identifying therapeutic strategies that have shown promise in other in vivo models, like mice.
Myotonic Dystrophy	While more complex, zebrafish are also being utilized to model aspects of myotonic dystrophy, particularly the RNA toxicity mechanisms.

Fig.2 These are examples of the experimental approaches used for the phenotypic analysis of the zebrafish model of LAMA2-related congenital muscular dystrophy (CMD, LAMA2-MD). (OA Literature) Fig.1 Examples of experimental approaches used for the phenotypical analysis of the zebrafish LAMA2-related congenital muscular dystrophy (CMD, LAMA2-MD) model.¹

What We Can Offer

Our Advantage:

Customized Model Development: CBL offers bespoke MD zebrafish models tailored precisely to your research needs, including specific gene knockouts, knock-ins, and reporter lines, ensuring your project starts with the most relevant in vivo system.
High-Throughput Drug Screening: Leverage our advanced automated platforms for rapid and efficient screening of compound libraries, identifying potential drug candidates for MD in studies as short as 4 days.
Comprehensive Phenotypic Analysis: Benefit from our expertise in assessing a wide range of MD-relevant phenotypes, including muscle integrity, locomotion, cardiac function, and inflammation, all observable in real-time due to zebrafish optical transparency.
Advanced Biomarker Discovery & Validation: We provide robust analysis of mRNA and microRNA biomarkers, offering critical insights into disease progression and therapeutic response, crucial for your clinical translation.
Integrated Data Solutions: Our services include detailed data acquisition, rigorous statistical analysis, and expert interpretation, providing you with actionable insights that seamlessly integrate with your broader preclinical strategy.
Expert Scientific Consultation: Partner with our team of over 20 years of experience in biology and preclinical research, offering tailored scientific guidance and support at every stage of your MD project.

Related Services

CBL offers a suite of complementary services designed to support your entire drug discovery and development pipeline for muscular dystrophies:

Ready to transform your MD research? Contact our team today to discuss your project in detail and discover how our zebrafish models can provide the insights you need.

Contact Our Team for More Information and to Discuss Your Project.

Reference

Fabian, Lacramioara, and James J Dowling. "Zebrafish Models of LAMA2-Related Congenital Muscular Dystrophy (MDC1A)." Frontiers in molecular neuroscience vol. 13 122. 9 Jul. 2020, doi:10.3389/fnmol.2020.00122. Distributed under Open Access license CC BY 4.0, without modification.

For Research Use Only. Not For Clinical Use.

In Vivo Services

Hot Products

Antibodies

Cells

Kits

Tracers

Gene Therapy Tools

Biospecimens

Cell Assay Reagents